Merck’s Keytruda faces 2028 biosimilar rights warning
Merck priced at $151.07 received a warning as Cipla’s U.S. subsidiary secured exclusive U.S. commercialization rights for Qilu Pharmaceutical’s proposed pembrolizumab biosimilar QL21.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.